Introduction
============

Cataract is the leading cause of blindness in the world \[[@r1],[@r2]\], is the leading cause of vision loss in the United States \[[@r3]\], and accounts for approximately 60% of Medicare costs related to vision \[[@r4]\]. Summary prevalence estimates indicate that 17.2% of Americans aged 40 years and older have cataract in either eye and 5.1% have pseudophakia or aphakia (previous cataract surgery). In addition to the implications for healthcare delivery and healthcare costs, cataract has been shown to be associated with falls and increased mortality \[[@r5]-[@r12]\], possibly because of associated systemic conditions. Women have a slightly higher risk of having cataract than men \[[@r13]\]. With increased life expectancy, the number of cataract cases and cataract surgeries is expected to increase dramatically unless primary prevention strategies can be developed and successfully implemented.

Several genetic loci have also been linked to cataract as an independent phenotypic trait. An extensive body of literature has addressed the role of genetics in childhood cataract \[[@r14]\], and it has been hypothesized that these same genes may be plausible candidates for age-related cataract \[[@r15]\]. It has been suggested that as many as 40 genes may be involved in age-related cataract \[[@r16]\]. Evidence for a major gene has been identified for cortical \[[@r17]\] and nuclear \[[@r18],[@r19]\] cataract, with heritability estimates of 58% \[[@r20]\] and 48% \[[@r21]\], respectively. A whole genome STR scan conducted in families in Wisconsin revealed a major locus for age-related cortical cataract on chromosome 6p12-q12 \[[@r22]\], and specific candidate genes that have been studied include *galactokinase* (Gene_ID: 2584; OMIM: [604313](http://www.ncbi.nlm.nih.gov/omim/?term=604313)) \[[@r23],[@r24]\], *apolipoprotein E* (Gene_ID: 348; OMIM: [107741](http://www.ncbi.nlm.nih.gov/omim/?term=107741)) \[[@r25]\], *glutathione S-transferase* (Gene_ID: 2944; OMIM: [138350](http://www.ncbi.nlm.nih.gov/omim/?term=138350))\[[@r26]\], *N-acetyltransferase 2* (Gene_ID: 10; OMIM: [612182](http://www.ncbi.nlm.nih.gov/omim/?term=612182)) \[[@r27],[@r28]\], and estrogen metabolism genes \[[@r29]\]. Two recent studies found an association between the *EPHA2* gene (Gene_ID: 1969; OMIM: [176946](http://www.ncbi.nlm.nih.gov/omim/?term=176946)) and cataract \[[@r30],[@r31]\].

Higher body mass index (BMI) has been shown in many studies to increase risk of cortical and posterior subcapsular (PSC) cataract (odds ratio \[OR\] = 1.5--2.5) \[[@r32]-[@r38]\]. A recent study found that nuclear cataract was not associated with obesity but was associated with the *FTO* obesity gene (Gene_ID: 79068; OMIM: [610966](http://www.ncbi.nlm.nih.gov/omim/?term=610966)) in an Asian population \[[@r39]\]. Although familial aggregation studies have shown a potential role for gene and environment interactions in nuclear cataract \[[@r40],[@r41]\], research in this area is limited. The association of glutathione S-transferase with cataract has been shown to be modified by smoking \[[@r42]\] and sunlight exposure \[[@r43]\]. No whole genome association SNP studies of age-related cataract in unrelated individuals have been reported in the medical literature. The purpose of this study was to conduct a genome-wide association study (GWAS) for age-related cataract and to prioritize top hits for further follow-up.

Methods
=======

Phenotypic data
---------------

The National Human Genome Research Institute (NHGRI)-funded electronic medical records and genomics (eMERGE) network implemented an electronic phenotype algorithm to select cataract cases and controls \[[@r44]\]. Cataracts as a condition were selected by Marshfield Clinic as its primary eMERGE phenotype, and the algorithm, which uses diagnostic and procedure codes, was developed by the Marshfield Clinic Personalized Medicine Research Project (PMRP) investigators \[[@r45]\]. The five sites in eMERGE-I include Marshfield Clinic, Group Health Research Institute, Vanderbilt University, Mayo Clinic, and Northwestern University. This study included four of the sites: Marshfield Clinic, Group Health Research Institute, Vanderbilt University, and Mayo Clinic. Using an algorithm for a specific phenotype, each participating site extracted study samples for a specific disease or phenotype from the electronic health records (EHR). Once samples had been selected and genotyped, they were available for phenotyping with additional algorithms. Thus, the cataract algorithm was deployed across the network. The cases and the controls had to meet the following inclusion criteria: The cases were age 50 years and older at the time of diagnosis or surgery, and the controls were age 50 years or older at the time of the most recent eye exam and had had an eye exam within the previous 5 years. The controls had no diagnostic codes for cataract or evidence of cataract surgery. The cases were identified as "surgical" or "diagnosis only." Surgical cases had undergone a cataract extraction in at least one eye. The diagnosis-only cases were required to have either cataract diagnoses on two or more dates or have one diagnosis date and natural language processing and optical character recognition (NLP/OCR) find one or more inclusion cataract terms. Cataract type was extracted from the notes using natural language processing and optical character recognition with validation through manual chart abstraction \[[@r45],[@r46]\].

Genotypic data
--------------

Genome-wide genotyping has been performed on approximately 17,000 samples across the network at the Broad Institute and at the Center for Inherited Disease Research (CIDR) using the Illumina 660W-Quad or 1M-Duo Beadchips (CIDR, Baltimore, MD). For this particular study, which includes predominantly individuals of European descent, we used only the Illumina 660W-Quad platform. This platform consists of 561,490 SNPs and 95,876 intensity-only probes. Genotyping calls were made at either CIDR or Broad using [BeadStudio](http://www.illumina.com/gsp/genomestudio_software.ilmn) version 3.3.7. The eMERGE Cataract dataset pre-quality control (QC) included 7,535 DNA samples and 344 HapMap controls: 3,968 Marshfield Clinic, 2,379 Group Health, 986 Mayo, and 202 Vanderbilt BioVU. Data were cleaned using the eMERGE QC pipeline developed by the eMERGE Genomics Working Group \[[@r47]\]. This process includes evaluation of the sample and marker call rate, gender mismatch, duplicate and HapMap concordance, batch effects, Hardy--Weinberg equilibrium, sample relatedness, and population stratification. After QC, 530,101 SNPs and 7,397 samples were used for analysis (see [Table 1](#t1){ref-type="table"} for distribution by site). All genotype data and a detailed QC report for each individual site, as well as the merged eMERGE dataset, can be found on [dbGaP](http://www.ncbi.nlm.nih.gov/gap), and the detailed eMERGE QC pipeline can be found in \[[@r47],[@r48]\].

###### Descriptive statistics on eMERGE cataract data set.

  Study sample                            Site                                               Number          Number Missing   Total
  --------------------------------------- ------------------- -------------- --------------- --------------- ---------------- ---------------
                                                                                             7397            0                7397
                                          Marshfield Clinic                  Total                                            3914 (52.91%)
                                                                             Cases           2557                             
                                                                             Controls        1357                             
                                          Mayo Clinic                        Total                                            952 (12.87%)
                                                                             Cases           606                              
                                                                             Controls        346                              
                                          Group Health                       Total                                            2346 (31.72%)
                                                                             Cases           2235                             
                                                                             Controls        111                              
                                          Vanderbilt                         Total                                            185 (2.50%)
                                                                             Cases           105                              
                                                                             Controls        80                               
                                          White                                              7109 (96.11%)                    
  Race                                    Black                                              114 (1.54%)     0                7397
  (p=0.1157)                                                                                                                  
                                          Other                                              174 (2.35%)                      
  Case-Control Cataract                                                      Cases           5503            0                7397
                                                                             Controls        1894                             
  Cataract Age at Diagnosis (Case only)                       Mean±SD        70.50±8.09      7296            101              7397
                                                              Median         71                                               
                                                              IQR(25%,75%)   (66,76)                                          
                                                              Range          35 - 136                                         
  Sex                                     Cases                              Male            2401            0                5503
  (p=0.7684)                                                                 Female          3102                             
                                          Controls                           Male            819             0                1894
                                                                             Female          1075                             
  Birthdate Year\*\*                      Cases               Mean±SD        2.3211±1.01     5462            41               5503
  (p\<0.0001)                                                 Median         2                                                
                                                              IQR(25%,75%)   (1,3)                                            
                                                              Range          1.000 - 5.000                                    
                                          Controls            Mean±SD        4.07±0.936      1893            1                1894
                                                              Median         4                                                
                                                              IQR(25%,75%)   (4,5)                                            
                                                              Range          1.000 - 6.000                                    
  Diabetes (p\<0.0001)                    Cases                              Yes             921             2613             5503
                                                                             No              1969                             
                                          Controls                           Yes             306             323              1894
                                                                             No              1265                             

\*\* Birthdate Year denotes decade of birth where 1=1910, 2=1920, 3=1930, 4=1940, 5=1950, 6=1960

Statistical analyses
--------------------

Single-locus tests of association were performed using [PLINK](http://pngu.mgh.harvard.edu/~purcell/plink/) \[[@r49]\] assuming an additive genetic model for all 530,101 SNPs in a total of 7,397 unrelated individuals (5,503 cases and 1,894 controls). We calculated principal components using the [EIGENSTRAT](http://genepath.med.harvard.edu/~reich/EIGENSTRAT.htm) program \[[@r50]\] and thus adjusted our analyses for the first three principal components (PCs) to avoid any spurious associations that can be caused due to population stratification. EIGENSTRAT is based on principal components analysis and is used to detect and correct for population stratification in genome-wide association studies. Thus, we present the results of the analysis adjusted by principal components 1--3 (PC1--3).

We also performed an age-at-diagnosis association analysis using cases only. Age at diagnosis is defined as the age when the first cataract diagnosis was made in the electronic health record. We performed unadjusted analysis and adjusted for PC1--3 using linear regression in PLINK. In [Table 2](#t2){ref-type="table"} and [Table 3](#t3){ref-type="table"}, we report all p values \<1×10^−5^. All associations identified by our analyses are suggestive and must be replicated in independent datasets because the signals did not reach a Bonferroni corrected genome-wide statistical significance level.

###### PC adjusted case-control association analysis results.

  CHR   SNP          Reference Allele   Case MAF   OR       P value    Gene           Left Gene      Right Gene       Type of Variant
  ----- ------------ ------------------ ---------- -------- ---------- -------------- -------------- ---------------- -----------------
  16    rs8044853    T                  0.335      0.7099   2.42E-06   NA             GAN            CMIP             NA
  9     rs1929494    T                  0.4391     1.217    2.46E-06   LOC100129210   ALDOB          C9orf125         intron
  22    rs926937     A                  0.045      0.8525   6.09E-06   NA             LOC100130624   MN1              NA
  16    rs9927153    A                  0.2391     0.8359   9.38E-06   NA             GAN            CMIP             NA
  16    rs2098753    G                  0.3183     0.8106   1.06E-05   NA             GAN            CMIP             NA
  5     rs9292118    A                  0.2659     1.193    1.17E-05   NA             LOC441073      MAP3K1           NA
  1     rs16853148   A                  0.059      1.28     0.000012   NA             PRDM2          RP1--21O18.1     NA
  5     rs13178221   T                  0.243      1.203    1.33E-05   NA             LOC441073      MAP3K1           NA
  9     rs882809     T                  0.3823     0.7482   1.48E-05   LOC100129210   ALDOB          LOC100129210     near-gene-5
  10    rs9299674    G                  0.3242     0.7436   1.53E-05   NA             LOC441550      LOC439953        NA
  10    rs4301693    C                  0.1521     1.184    1.84E-05   NA             LOC441550      LOC439953        NA
  2     rs10197959   A                  0.4305     0.8409   1.87E-05   DNER           PID1           LOC100130031     intron
  16    rs1563655    A                  0.3251     0.8514   2.04E-05   NA             GAN            CMIP             NA
  2     rs4853633    T                  0.1937     1.241    2.17E-05   NA             MSTN           MGC13057         NA
  15    rs8027435    T                  0.4498     1.235    2.23E-05   NA             ARRDC4         LOC728459        NA
  3     rs13074058   C                  0.0789     0.8423   0.000028   LOC285382      VPS8           EHHADH           intron
  10    rs549676     C                  0.4961     1.219    3.19E-05   NA             PITRM1         KLF6             NA
  2     rs10864871   C                  0.2922     0.7878   3.26E-05   NA             hCG_2045614    LOC728241        NA
  6     rs9405313    A                  0.1204     0.7855   3.31E-05   NA             LY86           RP11--320C15.1   NA
  4     rs4695885    C                  0.3323     1.222    3.96E-05   NA             LOC100128266   FBXO8            NA
  4     rs2015977    A                  0.4608     0.5185   4.08E-05   NA             LOC391656      LOC100131441     NA
  16    rs310011     G                  0.4267     0.8545   4.39E-05   NA             GAN            CMIP             NA
  3     rs3732933    A                  0.0718     1.181    4.42E-05   EHHADH         C3orf70        EIF2S2P2         reference
  12    rs7963343    C                  0.1752     1.203    4.49E-05   LOC100129881   CRADD          LOC441644        intron
  20    rs6073358    T                  0.0897     0.8249   4.57E-05   JPH2           TOX2           C20orf111        intron
  18    rs7244678    C                  0.0764     1.183    6.02E-05   IMPA2          MPPE1          LOC646044        intron
  19    rs7252479    A                  0.0516     0.8323   6.02E-05   ZNF578         LOC441862      ZNF808           intron
  15    rs1993976    A                  0.4469     0.7933   6.74E-05   NA             ARRDC4         LOC728459        NA
  3     rs17008958   A                  0.1439     0.7515   7.02E-05   EIF4E3         FOXP1          GPR27            intron
  13    rs943386     G                  0.324      1.258    7.13E-05   NA             LOC646208      LOC100130029     NA
  17    rs4531770    C                  0.1407     0.8437   0.000072   NA             hCG_1644301    FLJ37644         NA
  5     rs3850653    A                  0.2327     1.178    7.26E-05   NA             MEF2C          LOC729011        NA
  1     rs10746432   A                  0.4345     0.8413   7.53E-05   HHAT           LOC100129235   KCNH1            intron
  5     rs160044     T                  0.3105     1.232    7.62E-05   MEF2C          LOC645323      LOC729011        intron
  3     rs1447899    T                  0.2838     1.246    0.00008    EIF4E3         FOXP1          GPR27            intron
  12    rs4831958    T                  0.0711     0.8469   8.04E-05   NA             LOC100130336   LOC100131830     NA
  4     rs6814129    G                  0.4445     1.217    8.11E-05   NA             MRPS36P2       LOC644325        NA
  9     rs12347205   A                  0.3934     1.21     8.47E-05   NA             IL6RL1         OR7E31P          NA
  9     rs951611     T                  0.0095     0.8008   9.12E-05   NA             LOC286239      LOC401497        NA
  1     rs4951508    T                  0.2343     0.7486   9.58E-05   HHAT           LOC100129235   KCNH1            intron
  6     rs9379053    A                  0.1076     0.7166   9.65E-05   NA             LY86           RP11--320C15.1   NA
  20    rs1337906    C                  0.3422     1.179    9.84E-05   NA             RPL41P1        ST13P            NA
  9     rs2148996    T                  0.4654     0.8493   9.86E-05   NA             LOC392358      GAS1             NA
  19    rs7247032    T                  0.3922     0.7675   9.91E-05   NA             LOC100130084   USP29            NA
  8     rs4268128    A                  0.215      0.6761   9.97E-05   NA             TNFRSF10B      TNFRSF10C        NA

###### PC adjusted age-at-diagnosis association analysis results.

  CHR   SNP          Reference Allele   Case MAF   Beta      P value    Gene       Left Gene      Right Gene     Type of Variant
  ----- ------------ ------------------ ---------- --------- ---------- ---------- -------------- -------------- -----------------
  12    rs12296937   G                  0.0267     −1.08     6.39E-07   ACSS3      LIN7A          PPFIA2         intron
  12    rs2574730    A                  0.0371     −1.003    3.04E-06   ACSS3      LIN7A          PPFIA2         intron
  12    rs769056     T                  0.0369     0.6454    3.39E-06   ACSS3      LIN7A          PPFIA2         intron
  12    rs11835432   T                  0.1937     0.6667    7.64E-06   NA         LOC100132564   LOC644489      NA
  1     rs207145     T                  0.1237     −0.6722   7.9E-06    NA         LOC645506      GOT2L1         NA
  12    rs2593270    A                  0.2593     −1.263    1.06E-05   NA         LOC100132564   LOC644489      NA
  12    rs2656824    G                  0.2529     0.7466    1.19E-05   NA         LOC100132564   LOC644489      NA
  15    rs4965818    G                  0.3444     −0.8272   1.37E-05   SNRPA1     SELS           PCSK6          intron
  12    rs337656     T                  0.2225     −0.7027   1.45E-05   NA         LOC643264      CLLU1OS        NA
  12    rs10778791   G                  0.0354     −0.7015   2.08E-05   ACSS3      LIN7A          PPFIA2         intron
  2     rs12612521   C                  0.2144     −0.6601   0.000024   NA         LOC728241      LOC100131284   NA
  2     rs10932058   C                  0.4981     −0.7464   2.68E-05   NA         LOC100132132   LOC100132669   NA
  15    rs748696     G                  0.4491     −0.6481   2.98E-05   KIAA1199   FAM108C1       LOC100128570   intron
  15    rs1524876    T                  0.4568     0.7457    3.57E-05   MTMR10     MTMR15         TRPM1          intron
  15    rs4778856    G                  0.4667     0.7429    3.77E-05   KIAA1199   FAM108C1       LOC100128570   intron
  9     rs2229594    T                  0.1722     0.7258    3.95E-05   BAAT       LOC347275      LOC100128665   utr-3
  16    rs933717     T                  0.435      0.6402    0.000041   FBXO31     LOC730018      MAP1LC3B       intron
  1     rs6663771    G                  0.4138     0.652     4.24E-05   NA         SPATA17        RRP15          NA
  15    rs1432442    G                  0.0913     0.6621    0.000043   MAP2K1     ATP5J2P6       SNAPC5         intron
  5     rs2468475    T                  0.473      −0.6838   4.59E-05   NA         LOC100128659   LOC729862      NA
  4     rs2406040    G                  0.266      0.8714    4.59E-05   NA         LOC646316      LOC729578      NA
  4     rs2406041    C                  0.2591     −1.213    0.000051   NA         LOC646316      LOC729578      NA
  2     rs13414831   G                  0.2974     −2.441    5.34E-05   NA         UBR3           MYO3B          NA
  20    rs864184     A                  0.2301     −1.864    0.000054   PHACTR3    LOC645605      SYPC2          intron
  4     rs10517073   T                  0.4173     −2.027    5.98E-05   ANAPC4     ZCCHC4         LOC645433      intron
  18    rs578026     C                  0.3204     −2.022    0.000061   CLUL1      CETN1          C18orf56       intron
  2     rs16857804   G                  0.2944     −0.8456   6.24E-05   NA         UBR3           MYO3B          NA
  2     rs4560089    G                  0.3525     1.146     6.35E-05   NA         LOC100130842   MRPL50P1       NA
  12    rs934078     A                  0.1049     −1.048    6.57E-05   NA         OSTF1P         TBX3           NA
  1     rs1416156    A                  0.4182     0.8037    6.96E-05   NA         SPATA17        RRP15          NA
  2     rs617222     A                  0.2478     0.8032    7.03E-05   NA         LOC100129746   EPHA4          NA
  4     rs2897305    G                  0.2646     0.8959    7.06E-05   NA         LOC646316      LOC729578      NA
  20    rs6070943    A                  0.1765     −0.6294   7.23E-05   PHACTR3    LOC645605      SYCP2          intron
  1     rs991007     T                  0.1118     0.656     7.26E-05   INADL      TM2D1          L1TD1          intron
  12    rs12099972   A                  0.0821     1.132     7.71E-05   NA         LOC100129881   LOC441644      NA
  2     rs9309489    A                  0.2321     −0.6522   7.86E-05   NA         TACR1          FAM176A        NA
  14    rs1742707    A                  0.4406     0.6657    7.97E-05   NA         CPSF2          SLC24A4        NA
  17    rs9908117    C                  0.2586     −0.7235   8.27E-05   NA         LOC100128284   WSCD1          NA
  9     rs7874443    C                  0.3182     −0.6617   8.34E-05   NA         GOLM1          LOC100130433   NA
  2     rs10195113   T                  0.0657     −0.7182   8.41E-05   NA         SLC8A1         LOC729984      NA
  5     rs1472606    G                  0.3331     −0.69     0.000085   NA         SFXN1          HRH2           NA
  18    rs7227421    G                  0.0358     −1.679    9.02E-05   GNAL       LOC729602      CHMP1B         intron
  10    rs4388822    T                  0.0717     −0.7606   9.14E-05   NA         LOC439992      GRID1          NA
  5     rs2277939    A                  0.3473     −0.8382   9.34E-05   SAP30L     GALNT10        HAND1          intron

Results
=======

[Figure 1](#f1){ref-type="fig"} shows the Manhattan plots for the single locus tests of association for cataract case control adjusted ([Figure 1A](#f1){ref-type="fig"}) and age-at-diagnosis adjusted ([Figure 1B](#f1){ref-type="fig"}) and [Figure 2](#f2){ref-type="fig"} shows the corresponding QQ plots for each GWAS analysis. Our top hits in the adjusted case-control analysis include *gigaxonin* (*GAN;* Gene_ID: 8139, OMIM: [605379](http://www.ncbi.nlm.nih.gov/omim/?term=605379); p value = 2.42×10^−6^), which encodes a member of the cytoskeletal Broad-Complex, Tramtrack, and Bric a brac (BTB/kelch) repeat family. The encoded protein plays a role in neurofilament architecture and is involved in mediating the ubiquitination and degradation of some proteins. Defects in this gene are a cause of giant axonal neuropathy (*GAN*). Other potential interesting findings include *DNER* (Gene_ID: 92737; OMIM: [607299](http://www.ncbi.nlm.nih.gov/omim/?term=607299); p value = 1.87×10^−5^), which encodes for the Delta and Notch-like epidermal growth factor-related receptor, and *EHHADH* (Gene_ID: 1962; OMIM: [607037](http://www.ncbi.nlm.nih.gov/omim/?term=607037); p value = 2.80×10^−5^) encodes for enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase. Myocyte-specific enhancer factor 2C also known as MADS box transcription enhancer factor 2, polypeptide C is a protein that in humans is encoded by the *MEF2C* gene (Gene_ID: 4208; OMIM: [600662](http://www.ncbi.nlm.nih.gov/omim/?term=600662); p value = 7.26×10^−5^). *MEF2C* upregulates the expression of the homeodomain transcription factors DLX5 and DLX6, two transcription factors that are necessary for craniofacial development \[[@r51]\]. This could be another interesting link to cataracts.
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Several SNPs in or near *ALDOB* (Gene_ID: 229; OMIM: [612724](http://www.ncbi.nlm.nih.gov/omim/?term=612724); p value = 2.46×10^−6^), which encodes for aldolase B, fructose-bisphosphate, were also associated with cataracts in our GWAS analysis. Mutations in this gene result in an autosomal recessive disorder of fructose intolerance, and cases of cataract have been reported in the first decade of life \[[@r52]\]. Another interesting associated gene is *MAP3K1* (Gene_ID: 4214; OMIM: [600982](http://www.ncbi.nlm.nih.gov/omim/?term=600982); p value = 1.33×10^−5^), a functional mitogen-activated protein kinase kinase kinase 1. Molecular signatures of *MAP3K1* have been shown to be important in embryonic eyelid closure in the mouse \[[@r53]\]. In total, 45 SNPs were statistically significant at p\<10^−5^ or smaller.

In the age-at-diagnosis analysis, our top hits include *ACSS3* (Gene_ID: 79611; OMIM: [614356](http://www.ncbi.nlm.nih.gov/omim/?term=614356); p value = 6.39×10^−7^), which is *acyl-CoA synthetase short-chain family member 3*; EPHA4 (p value = 7.03×10^−5^), ephrin type-A receptor 4, which is a protein that in humans is encoded by the *EPHA4* gene (Gene_ID: 2043; OMIM: [602188](http://www.ncbi.nlm.nih.gov/omim/?term=602188)). This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family, along with *EPHA2*. EPH and EPH-related receptors have been implicated in mediating developmental events, especially in the nervous system \[[@r54]\].

Discussion
==========

This study is the first genome-wide association study in age-related cataract reported in the literature. Cataract in type 2 diabetes has been investigated, and a region on chromosome 3p14.4--3p14.2 was identified in a Han Chinese population \[[@r55]\]. The five SNPs identified in that study do not show evidence of association in our eMERGE cataract GWAS. It is difficult to interpret these results, however, because age-related cataracts and cataracts in type 2 diabetics may be two different phenotypes, which may have disparate etiologies. In addition, our dataset does not have an overwhelming number of individuals with type 2 diabetes (see [Table 1](#t1){ref-type="table"}); thus, we were underpowered to explore this specific type of association. Other previously published research on gene mapping in cataracts supports a linkage region on chromosome 1 \[[@r56]\] and association with *EPHA2* \[[@r30],[@r31]\]. In our GWAS, we did not see evidence for association with *EPHA2*, although we did see association with *EPHA4*. One significant difference in this study is the phenotyping of cases and controls based on electronic health records (EHR) in population-based cohorts, rather than family-based samples. However, our study in addition to the literature supports the suggestion of cataract-susceptibility loci on chromosome 1. Replication studies and larger sample sizes are needed to validate and confirm these findings.

Although the eMERGE network has demonstrated the utility of electronic phenotyping in EHR for several traits \[[@r57]-[@r61]\], there are inherent challenges with this approach. For ophthalmic conditions specifically, the abundance of EHR coded information is extremely limited or, in some health systems, absent. Thus, sophisticated phenotyping strategies must be established \[[@r45],[@r46]\] Still, the success of the EHR and biobank approach for association studies is unprecedented. The ability to perform multiple GWAS simultaneously with no additional genotyping is an enormous benefit \[[@r58]\]. Once a set of patient samples has been genotyped on a genome-wide association platform, those data can be reused for multiple additional genotype-phenotype association studies. In particular, the eMERGE network has done quite a bit of this for quantitative traits and clinical laboratory variables such as cholesterol \[[@r60]\], red-blood cell indices \[[@r59]\], and white blood cell count \[[@r57]\]. The additional effort is expended on creating electronic phenotyping algorithms, rather than collecting samples and genotyping. Thus, this is an enormous resource for subsequent genotype-phenotype association studies.

Future explorations of age-related cataract include validating and replicating the association results identified herein. Unfortunately, because of the sample size and limited power by stratifying cases and controls by the eMERGE site, we did not have the opportunity to replicate these findings within eMERGE. The goal is to identify a similar study population where these results can be explored. In addition, we are beginning to investigate the role of gene--gene and gene--environment interactions associated with cataracts \[[@r62]\]. Due to the complexity of the trait, we hypothesize that the genetic architecture will be similar to that of other complex traits: multigenic with a combination of genetic and environmental interactions.

As demonstrated by this and other studies, the beauty of using an electronic health record is the ability to reuse genotyped samples for various phenotypes. The eMERGE network has clearly demonstrated the success of this study design, and continues to demonstrate the strengths and limitations of this approach.
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